Eftilagimod Alfa

Stage IV Melanoma

Immutep Australia Pty. Ltd.Phase 1Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 95/ 100

Competitive context

104 Active assets in the Stage IV Melanoma cohort.

Asset / Sponsor	Phase	Rating
Cediranib M.D. Anderson Cancer Center	Phase 2	BBB
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Ifa Craig L Slingluff, Jr	Phase 2	BB
Nivolumab Bristol-Myers Squibb	Phase 4	BB
Therapeutic Autologous Lymphocytes Fred Hutchinson Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Eftilagimod Alfa is also rated in:

non-small cell lung carcinomaDormant

BB

Indicative ·

66 / 100

breast adenocarcinomaDormant

B

Indicative ·

57 / 100

head and neck squamous cell carcinomaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.